Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy

Robert Ali; Junaid Arshad; Sofia Palacio; Raja Mudad

doi:10.2147/DDDT.S147499

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy

Robert Ali, Junaid Arshad, Sofia Palacio, Raja Mudad

Medicine

Research output: Contribution to journal › Review article

4 Scopus citations

Abstract

Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinical activity against crizotinib-resistant ALK mutant advanced NSCLC. The current review narrates a brief history of tyrosine kinases, the development and clinical background of brigatinib (including its pharmacology and molecular structure) and its use in ALK-positive NSCLC.

Original language	English (US)
Pages (from-to)	569-580
Number of pages	12
Journal	Drug design, development and therapy
Volume	13
DOIs	https://doi.org/10.2147/DDDT.S147499
State	Published - Jan 1 2019

Fingerprint

Keywords

ALK inhibitors
ALK positive
brigatinib
non-small cell lung cancer
TKI

ASJC Scopus subject areas

Pharmacology
Pharmaceutical Science
Drug Discovery

Cite this

Ali, R., Arshad, J., Palacio, S., & Mudad, R. (2019). Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy. Drug design, development and therapy, 13, 569-580. https://doi.org/10.2147/DDDT.S147499

@article{ffbb0f9a525540e0aca9e5834a3ea76d,

title = "Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy",

abstract = "Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinical activity against crizotinib-resistant ALK mutant advanced NSCLC. The current review narrates a brief history of tyrosine kinases, the development and clinical background of brigatinib (including its pharmacology and molecular structure) and its use in ALK-positive NSCLC.",

keywords = "ALK inhibitors, ALK positive, brigatinib, non-small cell lung cancer, TKI",

author = "Robert Ali and Junaid Arshad and Sofia Palacio and Raja Mudad",

year = "2019",

month = jan

day = "1",

doi = "10.2147/DDDT.S147499",

language = "English (US)",

volume = "13",

pages = "569--580",

journal = "Drug Design, Development and Therapy",

issn = "1177-8881",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Brigatinib for ALK-positive metastatic non-small-cell lung cancer

T2 - design, development and place in therapy

AU - Ali, Robert

AU - Arshad, Junaid

AU - Palacio, Sofia

AU - Mudad, Raja

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinical activity against crizotinib-resistant ALK mutant advanced NSCLC. The current review narrates a brief history of tyrosine kinases, the development and clinical background of brigatinib (including its pharmacology and molecular structure) and its use in ALK-positive NSCLC.

AB - Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinical activity against crizotinib-resistant ALK mutant advanced NSCLC. The current review narrates a brief history of tyrosine kinases, the development and clinical background of brigatinib (including its pharmacology and molecular structure) and its use in ALK-positive NSCLC.

KW - ALK inhibitors

KW - ALK positive

KW - brigatinib

KW - non-small cell lung cancer

KW - TKI

UR - http://www.scopus.com/inward/record.url?scp=85062167362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062167362&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S147499

DO - 10.2147/DDDT.S147499

M3 - Review article

C2 - 30804663

AN - SCOPUS:85062167362

VL - 13

SP - 569

EP - 580

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -

Access to Document

10.2147/DDDT.S147499